CompoAtlas

Restore ACTIV(TM)

Originaltext auf Französisch.

In Kanada zugelassenes natürliches Gesundheitsprodukt

Falls dieses Produkt in Frankreich verkauft würde

Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut QuelleTäglich höchstens, Erwachsene
Bromélaïne de tige

Quelle : Ananas comosus var. comosus - Tige

900.000 FCC PUNicht berechnet
Bromélaïne de tige

Quelle : Ananas comosus var. comosus - Tige

36 mgNicht berechnet
Vitamine B6

Quelle : Chlorhydrate de pyridoxine

0,33 mg660 µg
Serratiopeptidase

Quelle : Serratia marcescens E-15 - Cellule Entiière

150 mgNicht berechnet
Serratiopeptidase

Quelle : Serratia marcescens E-15 - Cellule Entiière

45.000 SPUNicht berechnet
Protéase bactérien2.000 Unités de protéase bactérienne du FCCNicht berechnet
Protéase bactérien40 mgNicht berechnet
Protéase

Quelle : Aspergillus flavus var. oryzae - En entier

140 mgNicht berechnet
Protéase

Quelle : Aspergillus flavus var. oryzae - En entier

70.000 FCC HUTNicht berechnet
Papaïne

Quelle : Carica papaya - fruit

750.000 FCC PUNicht berechnet
Papaïne

Quelle : Carica papaya - fruit

30 mgNicht berechnet
4-alpha-D-glucane glucanohydrolase

Quelle : Aspergillus flavus var. oryzae - En entier

50 Unités d'alpha-amylase dextrinifiante du FCCNicht berechnet
4-alpha-D-glucane glucanohydrolase

Quelle : Aspergillus flavus var. oryzae - En entier

5.000 FCC DUNicht berechnet
Triacylglycérol lipase

Quelle : Aspergillus niger - En entier

11,5 mgNicht berechnet
Triacylglycérol lipase

Quelle : Aspergillus niger - En entier

140 FIP LUNicht berechnet
Thiamine

Quelle : Mononitrate de thiamine

0,33 mg660 µg
Vitamine B12

Quelle : Méthylcobalamine

0,66 microgram1,32 µg
Calcium

Quelle : Chélate d'acide aminé de calcium

900 microgram1.800 µg
Magnésium

Quelle : Magnesium amino acid chelate

900 microgram1.800 µg
Manganèse

Quelle : Produit de chélation de manganèse et d'acide aminé

200 microgram400 µg
Phyllanthus emblica

Quelle : Phyllanthus emblica - fruit

2 mgNicht berechnet
1,4-bêta-D-Mannane mannanohydrolase

Quelle : Trichoderma reesei - en entier

625 FCC HCUNicht berechnet
1,4-bêta-D-Mannane mannanohydrolase

Quelle : Trichoderma reesei - en entier

10,3 mgNicht berechnet

Nicht arzneiliche Inhaltsstoffe

Copolymère d'acide méthacrylique, Hydroxypropyl méthylcellulose, Maltodextrine, Stéarate de magnésium

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
Adultesminimum : 19 ans2 Capsule1 Tous les jours

In Kanada zugelassene Verwendungen

Helps reduce and/or relieve postoperative cheek swelling and/or pain after dental surgery. Helps to reduce (symptoms such as) pain, quantity of secretion, inability to perceive smell and stuffy nose from ear, nose and/or throat infections. Mucolytic enzyme that helps break down mucous. Proteolytic Enzyme. Digestive enzyme. Digestive Aid. Helps digest proteins. Digestive enzyme(s). Source of/Provides antioxidants. Contributes to maintaining general health. Source of vitamin(s)/mineral(s)/vitamin(s) and mineral(s) to support biological functions which play a key role in the maintenance of good health. Source of vitamin(s)/mineral(s)/vitamin(s) and mineral(s), a factor/factors in normal growth and development. Source of vitamin(s)/mineral(s)/vitamin(s) and mineral(s), a factor/factors in the maintenance of good health.

Originaltext auf Englisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Known Adverse Reactions : Stop use if rash, difficulty breathing, hypersensitivity and/or severe allergy occur. Hypersensitivity/allergy has been known to occur; in which case, discontinue use. Stop use if hypersensitivity/allergy occurs. Stop use if hypersensitivity/allergy occurs. Stop use if hypersensitivity/allergy occurs. Stop use if hypersensitivity/allergy occurs. Stop use if hypersensitivity/allergy occurs. Stop use if laxative effect occurs.

Originaltext auf Englisch.

Cautions and Warnings : Consult a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant, breastfeeding, have a gastrointestinal lesion/ulcer, kidney or liver disorder, or are having surgery. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking anticoagulant/blood thinner or anti-inflammatory medications. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant or breastfeeding. Consult a health care practitioner health care provider/health care professional/doctor/physician prior to use if you have an allergy to latex or fruits (e.g. avocado, banana, chestnut, passion fruit, fig, melon, mango, kiwi, pineapple, peach, and tomato). Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use are taking an anticoagulant/blood thinner or anti-inflammatory medications. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant, breastfeeding, have a gastrointestinal lesion/ulcer or are having surgery. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant, breastfeeding or have diabetes. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant or breastfeeding. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking anticoagulant agents, anti-inflammatory agents, or antibiotics. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you have gastrointestinal lesions/ulcers or are having a surgery. Some people may experience gastrointestinal discomfort/disturbances. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant, breastfeeding, have gastrointestinal lesions/ulcers or are having surgery. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking anticoagulant agents or anti-inflammatory agents. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant or breastfeeding. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking blood thinners or anti-inflammatory agents. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you have diabetes. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you have gastrointestinal lesions/ulcers or are having surgery. Consult a health care practitioner/health care provider/health care professional/doctor/physician if you have or develop abdominal pain, nausea, fever or vomiting. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant or breastfeeding.

Originaltext auf Englisch.

Produktdaten

Inhaber
AST Enzymes
NPN oder DIN-HM
80129565
Status
Aktive Lizenz
Lizenzdatum
15. Februar 2024
Überarbeitungsdatum
Nicht angegeben
Form
Capsule
Verabreichungsweg
Orale
Art des Antrags
Générale (non traditionelle)

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 80129565

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Offizielle Warnhinweise (Health Canada)

Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:

  • Serratiopeptidase
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    SERRAPEPTASE

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gastrointestinal lesions/ulcers, a kidney or liver disorder, or are having surgery (Bhagat et al. 2013; Chopra et al. 2009; Al- Khateeb and Nusair 2008; Mazzone et al. 1990).

    Von Health Canada zitierte Quellen (4)
    • Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematische Übersicht
    • Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomisierte Studie
    • Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomisierte Studie
    • Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomisierte Studie

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or anti-inflammatory medications (Bhagat et al. 2013; Chopra et al. 2009; Al-Khateeb and Nusair 2008; Mazzone et al. 1990).

    Von Health Canada zitierte Quellen (4)
    • Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomisierte Studie
    • Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematische Übersicht
    • Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomisierte Studie
    • Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomisierte Studie

    Bekannte Nebenwirkungen

    Stop use if rash, difficulty breathing, hypersensitivity and/or severe allergy occur (Bhagat et al. 2013; Balagi 2007).

    Von Health Canada zitierte Quellen (1)
    • Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematische Übersicht

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Monografie von Health Canada vom 25. Juli 2025

  • Phyllanthus emblica
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    Amla - Phyllanthus Emblica

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).

    Von Health Canada zitierte Quellen (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Gilt für Produkte: providing more than 3 grams of amla, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).

    Von Health Canada zitierte Quellen (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Anwendungsbedingung: Amlapitta, Digestive tonic.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Anwendungsbedingung: Laxative.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).

    Von Health Canada zitierte Quellen (3)
    • CPhA 2002: Repchinsky C, editor-in-chief. Patient Self-Care: Helping Patients Make Therapeutic Choices. 1st edition. Ottawa (ON): Canadian Pharmacists Association; 2002.
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
    • Pray WS. Non-Prescription Product Therapeutics. 2nd edition. New York (NY): Lippincott Williams & Wilkins; 2006.

    Gegenanzeigen

    Anwendungsbedingung: Laxative.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).

    Von Health Canada zitierte Quellen (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Bekannte Nebenwirkungen

    Anwendungsbedingung: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.

    When using this product you may experience a laxative effect.

    Monografie von Health Canada vom 28. März 2025

Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.

Das Belegdatum dieser Zutatenliste ist unbekannt.

Das Produkt hat sich geändert? Fotografieren Sie die Verpackung.

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile